Islatravir

Gilead to present over 40 HIV research studies at HIV Glasgow 2024, including late-breaking data on lenacapavir for HIV prevention and Biktarvy for HIV treatment, highlighting a robust portfolio and future-looking pipeline focused on person-centered drug development strategies.

Gilead and MSD advance their once-weekly HIV treatment to Phase II trials after a 48-week study showed 94.2% of patients maintained viral loads below 50 copies m/L. The treatment combines MSD’s islatravir with Gilead’s lenacapavir, offering a long-acting alternative to daily HIV medications like Gilead’s Biktarvy.

The Phase II trial of islatravir (Merck) and lenacapavir (Gilead) showed high viral suppression rates in HIV-positive adults after 48 weeks, potentially making it the first weekly oral HIV regimen. The combination therapy maintained a 94.2% viral suppression rate, comparable to daily regimens, with no grade 3 or 4 treatment-related adverse events reported.

Gilead Sciences and MSD's antiretroviral combination, islatravir and Sunlenca, maintained HIV suppression with a single weekly oral dose in a phase 2 trial, advancing to phase 3. The regimen showed non-inferior efficacy compared to daily Biktarvy, potentially improving adherence and reducing stigma.

Gilead and Merck announce Phase 2 data on islatravir and lenacapavir, showing 94.2% viral suppression at 48 weeks, advancing to Phase 3 for potential weekly oral HIV treatment.

Gilead and Merck presented Week 48 results from a phase 2 study evaluating a once-weekly oral combination of islatravir and lenacapavir for HIV-suppressed patients, showing comparable viral suppression rates to daily Biktarvy. The combination, not yet approved, will advance to phase 3 trials.

Gilead Sciences and Merck presented Phase 2 study results at IDWeek 2024 showing islatravir and lenacapavir maintained high viral suppression in virologically suppressed adults at 48 weeks. No participants had a viral load ≥50 copies/mL. The study supports further development of this once-weekly oral combination for HIV treatment.

Gilead and Merck's Phase 2 study shows islatravir and lenacapavir maintained high viral suppression in HIV-1 patients at 48 weeks, with no viral load >50 copies/mL. Adverse events were minimal, with 19.2% in ISL + LEN group and 5.8% in Biktarvy group experiencing treatment-related issues.